Fingolimod following natalizumab in RRMS: clinical and MRI findings

被引：0
|
作者：
Rinaldi, F. [1 ]
Seppi, D. [1 ]
Calabrese, M. [1 ]
Perini, P. [1 ]
Gallo, P. [1 ]
机构：
[1] Multiple Sclerosis Ctr, Padua, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：462 / 462
页数：1
相关论文
共 50 条
  • [1] Follow up of multiple sclerosis patients receiving fingolimod treatment: switching of natalizumab to treatment with fingolimod, clinical and MRI findings
    Evangelopoulos, M. E.
    Andreadou, E.
    Panagiotou, M.
    Psaltaki, M.
    Kemanetzoglou, E.
    Kilidireas, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 243 - 244
  • [2] Second-line use of Fingolimod in RRMS is as effective as natalizumab
    Braune, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 450 - 450
  • [3] Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
    Pfeuffer, Steffen
    Schmidt, Rene
    Straeten, Frederike Anne
    Pul, Refik
    Kleinschnitz, Christoph
    Wieshuber, Marinus
    Lee, De-Hyung
    Linker, Ralf A.
    Doerck, Sebastian
    Straeten, Vera
    Windhagen, Susanne
    Pawlitzki, Marc
    Aufenberg, Christoph
    Lang, Michael
    Eienbroeker, Christian
    Tackenberg, Bjoern
    Limmroth, Volker
    Wildemann, Brigitte
    Haas, Juergen
    Klotz, Luisa
    Wiendl, Heinz
    Ruck, Tobias
    Meuth, Sven G.
    JOURNAL OF NEUROLOGY, 2019, 266 (01) : 165 - 173
  • [4] Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
    Steffen Pfeuffer
    Rene Schmidt
    Frederike Anne Straeten
    Refik Pul
    Christoph Kleinschnitz
    Marinus Wieshuber
    De-Hyung Lee
    Ralf A. Linker
    Sebastian Doerck
    Vera Straeten
    Susanne Windhagen
    Marc Pawlitzki
    Christoph Aufenberg
    Michael Lang
    Christian Eienbroeker
    Björn Tackenberg
    Volker Limmroth
    Brigitte Wildemann
    Jürgen Haas
    Luisa Klotz
    Heinz Wiendl
    Tobias Ruck
    Sven G. Meuth
    Journal of Neurology, 2019, 266 : 165 - 173
  • [5] Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
    Kappos, Ludwig
    Radue, Ernst-Wilhelm
    Comi, Giancarlo
    Montalban, Xavier
    Butzkueven, Helmut
    Wiendl, Heinz
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Derfuss, Tobias
    Naegelin, Yvonne
    Sprenger, Till
    Mueller-Lenke, Nicole
    Griffiths, Sarah
    von Rosenstiel, Philipp
    Gottschalk, Rebecca
    Zhang, Ying
    Dahlke, Frank
    Tomic, Davorka
    NEUROLOGY, 2015, 85 (01) : 29 - 39
  • [6] Fingolimod withdrawalClinical and MRI rebound in a patient with RRMS: case report
    Reactions Weekly, 2013, 1460 (1) : 22 - 22
  • [7] Clinical and MRI outcomes in fingolimod-treated relapsing remitting multiple sclerosis (RRMS) patients previously exposed to natalizumab: an 18-month follow-up
    Rinaldi, F.
    Miante, S.
    Perini, P.
    Seppi, D.
    Atzori, M.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 249 - 249
  • [8] Development of cerebral oxygen consumption over time in RRMS patients after treatment with natalizumab or fingolimod
    Knudsen, Maria Hojberg
    Cramer, Stig
    Vestergaard, Mark
    Lindberg, Ulrich
    Battistini, Jette Lautrup
    Larsson, Henrik
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 907 - 907
  • [9] Natalizumab improves MRI markers suggestive of irreversible tissue damage in RRMS
    Oreja-Guevara, C.
    Royo, A.
    Noval, S.
    Rodriguez de Antonio, L.
    Chamorro, B.
    Moreno, J.
    Diez-Tejedor, E.
    Alvarez-Linera, J.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 216 - 217
  • [10] Follow-up of multiple sclerosis (MS) patients after natalizumab interruption. Clinical and MRI findings. Switching to treatment with fingolimod
    Evangelopoulos, M. E.
    Andreadou, E.
    Deligianni, C.
    Saltogiannis, G.
    Chasalevris, I.
    Chaina, V.
    Kilidireas, C.
    JOURNAL OF NEUROLOGY, 2013, 260 : S68 - S68
12345